GERN
HealthcareGeron Corporation · Biotechnology · $820M
What is Geron Corporation?
Geron Corporation is a late-stage clinical biopharmaceutical company focused on treating myeloid blood cancers. Headquartered in Foster City, California, it has concentrated its pipeline on a single investigational asset.
Geron develops imetelstat, a telomerase inhibitor designed to block the uncontrolled growth of malignant stem cells in hematologic myeloid malignancies. The drug is currently in Phase 3 clinical trials targeting myelodysplastic syndromes and myelofibrosis. Revenue generation depends on regulatory approval and eventual commercialization of this single pipeline candidate.
Geron was incorporated in 1990 and is based in Foster City, California.
- Imetelstat — telomerase inhibitor in Phase 3 trials
- Myelodysplastic syndromes (MDS) program
- Myelofibrosis treatment program
Is GERN a Good Stock to Buy?
UQS Score rates GERN as Below Average overall.
Growth stands out as the strongest pillar, reflecting the clinical-stage momentum behind imetelstat. The Risk pillar also registers as Good, suggesting the company's near-term financial runway is relatively managed for a pre-revenue biotech.
Quality and Moat both score Weak, consistent with a company that has no approved products and no established competitive position yet.
See the exact pillar breakdown and full financial metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does GERN pay dividends?
No — Geron Corporation does not currently pay a dividend.
Geron does not pay a dividend. As a clinical-stage company with no commercial revenue, available capital is directed toward advancing imetelstat through Phase 3 trials and preparing for potential regulatory submission rather than returning cash to shareholders.
When does GERN report earnings?
Geron Corporation reports financial results on a quarterly cadence, typical for US-listed equities.
As a pre-revenue biopharmaceutical company, quarterly results center on operating expenses, cash burn, and clinical trial updates rather than traditional revenue metrics. Key milestones to watch involve regulatory and trial progress for imetelstat.
For the most recent quarter's results, visit Geron Corporation's investor relations page.
GERN Price History
+8.7% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Geron Corporation?
Based on Geron Corporation's historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
Frequently Asked Questions
What does Geron Corporation do?
Geron is a late-stage clinical biopharmaceutical company developing imetelstat, a telomerase inhibitor, for myeloid blood cancers including myelodysplastic syndromes and myelofibrosis. The company has no approved products yet and is working toward regulatory milestones.
Does GERN pay dividends?
No, Geron does not pay a dividend. The company is pre-revenue and allocates its capital to clinical development rather than shareholder distributions.
When does GERN report earnings?
Geron reports on a standard quarterly schedule. Because our data source does not cover specific upcoming dates, check Geron's investor relations page for the latest earnings calendar.
Is GERN a good stock to buy?
UQS Score rates GERN as Below Average overall. Growth scores Strong, reflecting clinical-stage progress, but Quality and Moat are both Weak. The complete pillar breakdown is available to Pro members.
Is GERN overvalued?
The UQS Valuation pillar for GERN is rated Neutral, meaning the market price is neither clearly attractive nor elevated relative to the company's current profile. Full valuation metrics are available in the Pro view.
What is GERN's market cap bracket?
Geron Corporation is classified as a small-cap stock, which is typical for clinical-stage biotechs that have not yet reached commercial revenue.
Is GERN a long-term quality investment?
From a long-term quality standpoint, GERN's Weak scores in Quality and Moat reflect the absence of approved products and durable competitive advantages today. The Growth pillar is Strong, but long-term quality depends heavily on imetelstat's regulatory outcome.
Who founded Geron Corporation?
Geron Corporation was incorporated in 1990. Founding details are widely available through public company filings and Geron's official corporate history page.
Unlock Full GERN Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the exact UQS pillar scores across Quality, Growth, Moat, Risk, and Valuation
- ✓Access full financial metrics and trend data
- ✓Compare GERN against sector peers on every pillar
- ✓Get the complete analyst-style quality breakdown in one place
Pro Analysis
GERN — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 18, 2026 | 50.0 | 12.9 | 20.0 | 100.0 | 71.3 | 73.6 | +0.5 |
| May 15, 2026 | 49.5 | 12.9 | 20.0 | 100.0 | 71.3 | 70.8 | 0.0 |
| May 14, 2026 | 49.5 | 12.9 | 20.0 | 100.0 | 71.3 | 70.6 | -0.1 |
| May 12, 2026 | 49.6 | 12.9 | 20.0 | 100.0 | 71.3 | 71.0 | +2.0 |
| May 3, 2026 | 47.6 | 12.9 | 20.0 | 100.0 | 71.1 | 58.1 | -0.1 |
| Apr 29, 2026 | 47.7 | 12.9 | 20.0 | 100.0 | 71.1 | 58.8 | +0.4 |
| Apr 26, 2026 | 47.3 | 12.9 | 20.0 | 100.0 | 71.1 | 55.8 | +0.2 |
| Apr 19, 2026 | 47.1 | 12.9 | 20.0 | 100.0 | 71.1 | 54.7 | +0.1 |
| Apr 14, 2026 | 47.0 | 12.9 | 20.0 | 100.0 | 71.1 | 54.3 | -0.1 |
| Apr 2, 2026 | 47.1 | 12.9 | 20.0 | 100.0 | 71.1 | 54.8 | — |
GERN — Pillar Breakdown
Quality
— 12.9/100 (25%)Geron Corporation currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 100.0/100 (20%)Geron Corporation is growing rapidly with strong revenue and earnings expansion.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Analyst consensus for future earnings growth.
Risk
— 71.3/100 (15%)Geron Corporation maintains a reasonable risk profile with manageable debt levels.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 73.2/100 (15%)Geron Corporation trades at a reasonable valuation with decent earnings yield and FCF multiples.
Inverse of forward P/E — higher yield means cheaper stock.
P/E relative to earnings growth — lower is more attractive.
Moat
— 20/100 (25%)Geron Corporation operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for GERN.
Score Composition
Financial Data
More Stock Analysis
How is the GERN UQS Score Calculated?
The UQS (Unified Quality Score) for Geron Corporation is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Geron Corporation's competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Geron Corporation is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.